Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018

Meropenem-vaborbactam is approved to treat hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), in Europe. Meropenem-vaborbactam activity was evaluated against 3,193 Pseudomonas aeruginosa and 4,790 Enterobacterales isolates causing pneumonia, including VAP, in hospita...

Descripción completa

Detalles Bibliográficos
Autores principales: Carvalhaes, Cecilia G., Shortridge, Dee, Sader, Helio S., Castanheira, Mariana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Epidemiology and Surveillance
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7038313/
https://www.ncbi.nlm.nih.gov/pubmed/31907187
http://dx.doi.org/10.1128/AAC.02177-19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7038313/
https://www.ncbi.nlm.nih.gov/pubmed/31907187
http://dx.doi.org/10.1128/AAC.02177-19

Ejemplares similares